DOP2022000268A - Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantigeno y sus métodos de uso - Google Patents

Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantigeno y sus métodos de uso

Info

Publication number
DOP2022000268A
DOP2022000268A DO2022000268A DO2022000268A DOP2022000268A DO P2022000268 A DOP2022000268 A DO P2022000268A DO 2022000268 A DO2022000268 A DO 2022000268A DO 2022000268 A DO2022000268 A DO 2022000268A DO P2022000268 A DOP2022000268 A DO P2022000268A
Authority
DO
Dominican Republic
Prior art keywords
hlai
neoantigen
classical
complex
methods
Prior art date
Application number
DO2022000268A
Other languages
English (en)
Spanish (es)
Inventor
Weidanz Jon
Upchurch-Ange Katherine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of DOP2022000268A publication Critical patent/DOP2022000268A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DO2022000268A 2020-06-01 2022-11-28 Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantigeno y sus métodos de uso DOP2022000268A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032747P 2020-06-01 2020-06-01
US17/199,205 US11359023B2 (en) 2020-06-01 2021-03-11 Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
PCT/US2021/035290 WO2021247607A1 (en) 2020-06-01 2021-06-01 Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use

Publications (1)

Publication Number Publication Date
DOP2022000268A true DOP2022000268A (es) 2023-01-15

Family

ID=75495114

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000268A DOP2022000268A (es) 2020-06-01 2022-11-28 Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantigeno y sus métodos de uso

Country Status (20)

Country Link
US (4) US10981996B1 (cg-RX-API-DMAC10.html)
EP (1) EP4157882A4 (cg-RX-API-DMAC10.html)
JP (1) JP7650351B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230019468A (cg-RX-API-DMAC10.html)
CN (1) CN116367865A (cg-RX-API-DMAC10.html)
AR (1) AR122501A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021284275A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022024275A2 (cg-RX-API-DMAC10.html)
CA (1) CA3174090A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003336A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022018426A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220652A (cg-RX-API-DMAC10.html)
DO (1) DOP2022000268A (cg-RX-API-DMAC10.html)
EC (1) ECSP22097197A (cg-RX-API-DMAC10.html)
IL (1) IL298020A (cg-RX-API-DMAC10.html)
JO (1) JOP20220309A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022015114A (cg-RX-API-DMAC10.html)
PE (1) PE20230306A1 (cg-RX-API-DMAC10.html)
TW (1) TW202235439A (cg-RX-API-DMAC10.html)
WO (1) WO2021247607A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531255A (ja) * 2018-07-23 2021-11-18 アベクサ バイオロジクス，インク． 非古典的ｈｌａ−ｉおよびネオアンチゲンを含む複合体を標的とする抗体、およびその使用方法
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US20250223363A1 (en) * 2022-04-08 2025-07-10 Tizona Therapeutics, Inc. Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2010019921A2 (en) * 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
CN103773775B (zh) 2014-01-26 2015-11-18 江苏省农业科学院 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用
KR20170020868A (ko) 2014-06-20 2017-02-24 바이오얼라이언스 씨.브이. 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
JP7054397B2 (ja) 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
EP3573997A4 (en) 2017-01-24 2020-12-09 Abexxa Biologics, Inc. METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER
CN112351795A (zh) 2018-02-23 2021-02-09 安贝科思生物制剂公司 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
JP2021531255A (ja) 2018-07-23 2021-11-18 アベクサ バイオロジクス，インク． 非古典的ｈｌａ−ｉおよびネオアンチゲンを含む複合体を標的とする抗体、およびその使用方法
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US10981997B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use

Also Published As

Publication number Publication date
CL2022003336A1 (es) 2023-06-23
US20220332831A1 (en) 2022-10-20
CA3174090A1 (en) 2021-12-09
WO2021247607A1 (en) 2021-12-09
MX2022015114A (es) 2023-03-24
CR20220652A (es) 2023-07-03
PE20230306A1 (es) 2023-02-13
JOP20220309A1 (ar) 2022-11-15
IL298020A (en) 2023-01-01
ECSP22097197A (es) 2023-02-28
US20240026007A1 (en) 2024-01-25
BR112022024275A2 (pt) 2023-05-02
US10981996B1 (en) 2021-04-20
AR122501A1 (es) 2022-09-14
TW202235439A (zh) 2022-09-16
KR20230019468A (ko) 2023-02-08
JP2023530036A (ja) 2023-07-12
US20210371532A1 (en) 2021-12-02
CO2022018426A2 (es) 2022-12-30
US11359023B2 (en) 2022-06-14
CN116367865A (zh) 2023-06-30
US12173072B2 (en) 2024-12-24
AU2021284275A1 (en) 2023-01-19
JP7650351B2 (ja) 2025-03-24
EP4157882A1 (en) 2023-04-05
EP4157882A4 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
ECSP22097197A (es) Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso
CO2022008407A2 (es) Anticuerpos específicos para cd47, pd–l1 y sus usos
AR122502A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
ECSP22097203A (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
MX2020007880A (es) Anticuerpos de mica/b y metodos de uso.
CO2021007956A2 (es) Anticuerpo humanizado anti-pd-1 humana
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
CL2022002647A1 (es) Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CY1122036T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
CL2023000701A1 (es) Anticuerpos que se unen a il1rap y usos de los mismos
CY1119335T1 (el) Ποντικοι με περιορισμενη βαρια αλυσιδα ανοσοσφαιρινης
GT201400045A (es) Anticuerpo anti-abtcr
CO6280542A2 (es) Anticuerpos bivalentes bioespecificos en donde en una cadena ligera y una cadena pesada, los dominios variables vl y vh estan reeplazados el uno por el otro
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
PE20191031A1 (es) ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
MX2021015882A (es) Fragmentos de unión a antígeno egfr y composiciones que los comprenden.
MX2019007984A (es) Apareamiento preferido de dominios de anticuerpos.
BR112022014487A2 (pt) Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo
CO2023004381A2 (es) Anticuerpos cd1a y su uso
CL2020000920A1 (es) Anticuerpo monoclonal anti-il-5ra.
CL2024003486A1 (es) Anticuerpo anti-b7h3 y usos del mismo
CL2025003065A1 (es) Activadores de células t dirigidos a steap2 y composiciones de estos.
AR122983A1 (es) ANTICUERPOS ANTI-a4b7
BR112022021077A2 (pt) Anticorpos humanizados antifator bb de complemento e uso dos mesmos
BR112021020677A2 (pt) Anticorpos contra receptores de antígeno quimérico derivados de 4g7